News
PBM
1.000
-9.09%
-0.100
Weekly Report: what happened at PBM last week (0506-0510)?
Weekly Report · 8h ago
BILI, NUVO and MULN among pre-market losers
On the Move BILI, NUVO and MULN among pre-market losers. GreenPower Motor Company (GP) -40% announces proposed underwritten offering of common shares. Walt Disney Co ( DIS) also among those losing ground in the market.
Seeking Alpha · 6d ago
CRVS, CTMX and NRXP are among premarket gainers
On the Move CRVS, CTMX and NRXP are among premarket gainers. XBP Europe Holdings (XBP) and Perficient (PRFT) are among the biggest premarket losers. Bitcoin reclaims the $65K level.
Seeking Alpha · 05/06 12:39
Weekly Report: what happened at PBM last week (0429-0503)?
Weekly Report · 05/06 12:05
12 Health Care Stocks Moving In Wednesday's Intraday Session
CytomX Therapeutics stock increased by 154.6% to $4.15 during Wednesday's regular session. Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 36.79%. CVRx and Mobile-health Network among the losers.
Benzinga · 05/01 16:31
Weekly Report: what happened at PBM last week (0422-0426)?
Weekly Report · 04/29 12:13
Weekly Report: what happened at PBM last week (0415-0419)?
Weekly Report · 04/22 11:58
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Benzinga's psychedelic headlines roundup includes a look at the first two weeks of April 2024. Psilocybin could alter mechanisms associated with major depression and neurodegenerative diseases. Ancient Romans used to trip on hallucinogenic plants, archeologists say. Psycon's 2024 edition will take place in Colorado in May.
Benzinga · 04/17 13:13
Psyence Biomed Announces Phase IIb Clinical Trial Listing On The Australian New Zealand Clinical Trials Registry
Psyence Biomed's upcoming Phase IIb clinical trial of nature-derived psilocybin in patients diagnosed with Adjustment Disorder following an advanced cancer diagnosis has been listed on the Australian New Zealand Clinical Trials Registry. The randomized, double-blind, placebo-controlled study will test 84 patients in conjunction with psychotherapy. The Company anticipates enrolling the first subject in the second quarter of 2024.
Benzinga · 04/17 12:01
PSYENCE BIOMED ANNOUNCES PHASE IIB CLINICAL TRIAL LISTING ON THE AUSTRALIAN NEW ZEALAND CLINICAL TRIALS REGISTRY (ANZCTR)
Reuters · 04/17 12:00
PSYENCE BIOMEDICAL LTD: ANTICIPATES ENROLLING FIRST SUBJECT IN Q2 OF 2024 AND EXPECTS PRIMARY ENDPOINT RESULTS TO BE AVAILABLE IN 2025
Reuters · 04/17 12:00
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Psyence Group Inc is a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing. Psyence Australia has entered into a partnership with Fluence to support an upcoming Phase llb clinical trial. The company's Australian subsidiary is a subsidiary of Psyence Group.
Barchart · 04/16 10:01
Weekly Report: what happened at PBM last week (0408-0412)?
Weekly Report · 04/15 11:48
PSYENCE BIOMEDICAL LTD: EXPECTS PRIMARY ENDPOINT RESULTS TO BE AVAILABLE IN 2025 FOR DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIB STUDY
Reuters · 04/08 12:05
Weekly Report: what happened at PBM last week (0401-0405)?
Weekly Report · 04/08 11:54
Weekly Report: what happened at PBM last week (0325-0329)?
Weekly Report · 04/01 11:51
Weekly Report: what happened at PBM last week (0318-0322)?
Weekly Report · 03/25 11:54
12 Health Care Stocks Moving In Friday's After-Market Session
Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The company's market cap stands at $8.0 billion. Masimo shares rose 12.48% and NextCure shares declined by 9.5% during the same session.
Benzinga · 03/22 21:33
STEM, SOUN and GRFS among pre-market losers & stocks
On the Move STEM, SOUN and GRFS among pre-market losers & stocks. Ispire Technology, Lululemon Athletica and Cutera among the losers after Q4 earnings release. NKE, STEM, XTLB, ETPBM, BTOG, and SOUN among the winners.
Seeking Alpha · 03/22 12:23
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement. Psychedelics biopharma company Cybin Inc. Announced that the FDA has granted it a breakthrough therapy designation for its LSD-based treatment for anxiety disorder. The company also announced the pricing of an underwritten offering of $175 million in shares.
Benzinga · 03/20 18:49
More
Webull provides a variety of real-time PBM stock news. You can receive the latest news about Psyence Biomedical Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About PBM
Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.